A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).
Saved in:
| Title: | A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM). |
|---|---|
| Authors: | Nagarajan C; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Jen WY; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Ooi M; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., De Mel S; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Soekojo C; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Yoon SS; Seoul National University Hospital, Seoul, South Korea., Tan M; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Chen Y; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Li X; Singapore Clinical Research Institute, Singapore, Singapore., Pokharkar Y; Singapore Clinical Research Institute, Singapore, Singapore., Tham SN; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Hashim NSB; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Awasthi N; Singapore Clinical Research Institute, Singapore, Singapore., Burkill SM; Singapore Clinical Research Institute, Singapore, Singapore., Durie B; Cedars-Sinai Medical Center, Los Angeles, USA., Chng WJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. mdccwj@nus.edu.sg. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Jun 17; Vol. 15 (1), pp. 109. Date of Electronic Publication: 2025 Jun 17. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01296-8 |
